CELL INTELLIGENCE · 肿瘤细胞治疗研究

CAR-T 细胞疗法在实体瘤中的挑战与局限：为何获批仅限于血液系统恶性肿瘤？

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

肿瘤预激 CD8⁺ 自然杀伤 T 样细胞作为复发/难治性多发性骨髓瘤的高效新型细胞疗法

Tumor-priming CD8(+) natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma.

TPNC 是一种通过肿瘤驱动的致敏产生的新型细胞毒性淋巴细胞产品。

基于 CAR 的细胞与基因治疗：来自 ClinicalTrials.gov 的全球临床格局与新兴治疗策略

CAR-Based Cell and Gene Therapies: Global Clinical Landscape and Emerging Therapeutic Strategies from ClinicalTrials.gov.

接受 CAR-T 细胞治疗的血液系统恶性肿瘤患者中免疫效应细胞相关神经毒性的发生率：系统综述与荟萃分析

Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic rev

CAR-T 细胞疗法相关 ICANS 的总体发生率为全级别 26.9%、高级别 10.5%。